Skip to main content
. 2020 Dec 8;15:2331–2340. doi: 10.2147/CIA.S281865

Table 2.

Comparison of the Variables Stratified by Outcome in the Overall Cohort

Favorable Outcome
(n=113)
Poor Outcome
(n=143)
P-value Odds Ratio
(95% CI)
P-value
Age, mean (SD), y 65.7 (11.2) 69.9 (11.8) 0.004
Male, n (%) 70 (61.9) 69 (48.3) 0.029 2.043 (0.984–4.242) 0.055
Medical history, n (%)
 Hypertension 75 (66.4) 105 (73.4) 0.220
 Diabetes mellitus 12 (10.6) 31 (21.7) 0.019
Clinical characteristics, median (IQR)
 Baseline NIHSS score 14 (12–18) 17 (14–20) <0.001
 Baseline ASPECT score 9 (8–10) 8 (8–9) <0.001 0.680 (0.491–0.942) 0.020
Stroke cause, n (%)
 LAA 50 (44.2) 34 (23.8) <0.001
 Cardioembolic 47 (41.6) 94 (65.7)
 Undetermined or other 16 (14.2) 15 (10.5)
Occlusion site, n (%)
 ICA 33 (29.2) 74 (51.7) <0.001 2.663 (1.287–5.514) 0.008
 MCA 80 (70.8) 69 (48.3) Reference
OTP, median (IQR) 270 (224–303) 250 (210–300) 0.208
Bridging therapy, n (%) 16 (14.2) 16 (11.2) 0.475
Collateral score, n (%)
 Grade 0 8 (7.1) 50 (35.0) <0.001 Reference
 Grade 1 38 (33.6) 61 (42.7) 0.344 (0.119–0.994) 0.049
 Grade 2 57 (59.3) 32 (22.4) 0.115 (0.038–0.343) <0.001
mTICI, 2b/3, n (%) 98 (86.7) 89 (62.2) <0.001 0.223 (0.095–0.525) 0.001
SIRS, n (%) 13 (11.5) 78 (54.5) <0.001 4.112 (1.705–9.920) 0.002
Laboratory examination
 FBG* (mmol/L), mean (SD) 6.1 (2.2) 8.4 (4.0) <0.001
 Leucocytes, 109/L 9.3 (7.9–11.3) 11.8 (8.9–14.8) <0.001
 Neutrophils,109/L 7.7 (6.4–9.5) 10.1 (7.4–12.7) <0.001 1.171 (1.032–1.328) 0.015
 Lymphocytes, 109/L 1.1 (0.7–1.4) 0.8 (0.6–1.2) 0.005

Note: *Missing data in six patients.

Abbreviations: SIRS, systemic inflammatory response syndrome; ASPECT, Alberta Stroke Program Early CT; ICA, internal carotid artery; LAA, large-artery atherosclerosis; mTICI, modified thrombolysis in cerebral infarction; ICA, internal carotid artery; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; OTP, symptom onset to groin puncture time; FBG, fasting blood glucose.